Search

Displaying results 2691 - 2700 of 4539 in total
  1. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  2. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line.

    Products: ALDURAZYME 100 U/ML IV INFUZYON ICIN KONSANTRE COZELTI, 1 ADET
  3. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia.

  4. Drug

    Estrone

    go.drugbank.com/drugs/DB00655
    Approved

    Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.

  5. Drug

    Pirenzepine

    go.drugbank.com/drugs/DB00670
    ApprovedWithdrawn

    It is generally well tolerated by patients.

  6. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

  7. Drug

    Peginterferon alfa-2b

    go.drugbank.com/drugs/DB00022
    ApprovedInvestigational

    Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with [Ribavirin] or other antiviral drugs [FDA Label]. … Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors.

  8. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    It is being developed by Peptech.

  9. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  10. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options. … [L63927] Gedatolisib was approved by the FDA on July 14, 2026, in combination with [fulvestrant], with or without [palbociclib], for adults with HR-positive, HER2-negative locally advanced or metastatic